Pàgina inicial > Resultats de la cerca: Arnold, Douglas L
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 6 registres trobats en 0.02 segons.
Articles, 6 registres trobats
Articles 6 registres trobats  
1.
10 p, 683.9 KB Ozanimod in relapsing multiple sclerosis : Pooled safety results from the clinical development program / Selmaj, Krzysztof W. (University of Warmia and Mazury) ; Cohen, Jeffrey A. (Neurological Institute) ; Comi, Giancarlo (Vita-Salute San Raffaele University) ; Bar-Or, Amit (University of Pennsylvania) ; Arnold, Douglas Lorne (McGill University) ; Steinman, Lawrence (Stanford University Medical Center) ; Hartung, Hans-Peter (Medical University Vienna) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Kubala Havrdova, Eva (Charles University) ; Cree, Bruce A. C (UCSF University of California San Francisco) ; Minton, Neil (Bristol Myers Squibb) ; Sheffield, James K. (Bristol Myers Squibb) ; Ding, Ning (Bristol Myers Squibb) ; Kappos, Ludwig (University of Basel) ; Universitat Autònoma de Barcelona
Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for the treatment of relapsing multiple sclerosis (RMS). In phase 3 trials, ozanimod was well tolerated and superior to interferon beta-1a 30 µg once-weekly in reducing clinical and radiologic disease activity. [...]
2021 - 10.1016/j.msard.2021.102844
Multiple Sclerosis and Related Disorders, Vol. 51 (june 2021) , p. 102844  
Registre complet - Creative Commons
2.
15 p, 1.2 MB Five years of ocrelizumab in relapsing multiple sclerosis : OPERA studies open-label extension / Hauser, Stephen L. (University of California) ; Kappos, Ludwing (University of Basel) ; Arnold, Douglas Lorne (McGill University) ; Bar-Or, Amit (University of Pennsylvania) ; Brochet, Bruno (Department of Neurology. CHU de Bordeaux) ; Naismith, Robert (Washington University School of Medicine) ; Traboulsee, Anthony (University of British Columbia) ; Wolinsky, Jerry (University of Texas Health Science Center at Houston (UTHealth)) ; Belachew, Shibeshih (F. Hoffmann-La Roche Ltd) ; Koendgen, Harold (F. Hoffmann-La Roche Ltd) ; Levesque, Victoria (Genentech. Inc.) ; Manfrini, Marianna (F. Hoffmann-La Roche Ltd) ; Model, Fabian (F. Hoffmann-La Roche Ltd) ; Hubeaux, Stanislas (F. Hoffmann-La Roche Ltd) ; Mehta, Lahar (Genentech. Inc.) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona. Departament de Medicina
Objective: To assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA: I/II studies in relapsing multiple sclerosis. [...]
2020 - 10.1212/WNL.0000000000010376
Neurology, Vol. 95 Núm. 13 (september 2020) , p. E1854-E1867  
Registre complet - Creative Commons
3.
19 p, 537.2 KB Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis : Up to 5 years of follow-up in the DAYBREAK open-label extension trial / Cree, Bruce A. C (University of California) ; Selmaj, Krzysztof W. (University of Warmia and Mazury in Olsztyn) ; Steinman, Lawrence (Stanford University) ; Comi, Giancarlo (Vita-Salute San Raffaele University) ; Bar-Or, Amit (University of Pennsylvania) ; Arnold, Douglas Lorne (McGill University) ; Hartung, Hans-Peter (Medical University of Vienna) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Kubala Havrdova, Eva (Charles University) ; Sheffield, James K. (Bristol-Myers Squibb Company) ; Minton, Neil (Bristol-Myers Squibb Company) ; Cheng, Chun Yen (Bristol-Myers Squibb Company) ; Silva, Diego (Bristol-Myers Squibb Company) ; Kappos, Ludwig (University of Basel) ; Cohen, Jeffrey A. (Cleveland Clinic) ; Universitat Autònoma de Barcelona
Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for treatment of relapsing forms of MS. Objective: To characterize long-term safety and efficacy of ozanimod. [...]
2022 - 10.1177/13524585221102584
Multiple sclerosis, Vol. 28 Núm. 12 (2022) , p. 1944-1962  
Registre complet - Creative Commons
4.
9 p, 2.2 MB Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS / DeLuca, John (Rutgers - The State University of New Jersey, Newark) ; Schippling, Sven (University of Zurich) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Kappos, Ludwig (University of Basel) ; Cree, Bruce A. C (University of California, San Francisco) ; Comi, Giancarlo (Vita-Salute San Raffaele University) ; Arnold, Douglas Lorne (McGill University, Montreal) ; Hartung, Hans Peter (Heinrich Heine University Düsseldorf) ; Sheffield, James K. (Bristol-Myers Squibb Company) ; Liu, Hongjuan (Bristol-Myers Squibb Company) ; Silva, Diego (Bristol-Myers Squibb Company) ; Cohen, Jeffrey A. (Neurological Institute, Cleveland Clinic) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Cognitive dysfunction, including slowed cognitive processing speed (CPS), is one of the most disabling symptoms of multiple sclerosis (MS). The Symbol Digit Modalities Test (SDMT) is a preferred measure of CPS for MS trials and routine screening. [...]
2021 - 10.1016/j.msard.2020.102673
Multiple Sclerosis and Related Disorders, Vol. 48 (2021) , p. 102673  
Registre complet - Creative Commons
5.
14 p, 1.1 MB Present and future of the diagnostic work-up of multiple sclerosis : the imaging perspective / Filippi, Massimo (Vita-Salute San Raffaele University) ; Preziosa, Paolo (Vita-Salute San Raffaele University) ; Arnold, Douglas Lorne (McGill University) ; Barkhof, Frederik (University College London) ; Harrison, Daniel M. (Baltimore VA Medical Center) ; Maggi, Pietro (Centre Hospitalier Universitaire Vaudois) ; Mainero, Caterina (Harvard Medical School) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Sechi, Elia (University of Sassari) ; Weinshenker, Brian G. (University of Virginia) ; Rocca, Maria A. (Vita-Salute San Raffaele University) ; Universitat Autònoma de Barcelona
In recent years, the use of magnetic resonance imaging (MRI) for the diagnostic work-up of multiple sclerosis (MS) has evolved considerably. The 2017 McDonald criteria show high sensitivity and accuracy in predicting a second clinical attack in patients with a typical clinically isolated syndrome and allow an earlier diagnosis of MS. [...]
2022 - 10.1007/s00415-022-11488-y
Journal of Neurology, Vol. 270 (november 2022) , p. 1286-1299  
Registre complet - Creative Commons
6.
8 p, 976.6 KB Efficacy and safety of ozanimod in multiple sclerosis : Dose-blinded extension of a randomized phase II study / Cohen, Jeffrey A. (Mellen Center for MS Treatment and Research, Cleveland Clin) ; Comi, Giancarlo (Vita-Salute San Raffaele University) ; Arnold, Douglas Lorne (McGill University, Montreal) ; Bar-Or, Amit (University of Pennsylvania. Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology) ; Selmaj, Krzysztof W. (Center for Neurology, Łódź, Poland) ; Steinman, Lawrence (Stanford University Medical Center) ; Havrdová, Eva K. (Charles University. Department of Neurology and Center for Clinical Neuroscience) ; Cree, Bruce A. C. (University of California. UCSF Weill Institute for Neurosciences) ; Montalbán, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina) ; Hartung, Hans-Peter (Heinrich Heine University. Department of Neurology) ; Huang, Vivian (Celgene Corporation, San Diego, CA) ; Frohna, Paul (Celgene Corporation, San Diego, CA) ; Skolnick, Brett E. (Celgene Corporation, San Diego, CA) ; Kappos, Ludwig (University Hospital Basel (Basilea, Suïssa))
Ozanimod, an oral immunomodulator, selectively targets sphingosine 1-phosphate receptors 1 and 5. Evaluate efficacy, safety, and tolerability of ozanimod in relapsing multiple sclerosis. In the RADIANCE Part A phase II study (NCT01628393), participants with relapsing multiple sclerosis were randomized (1:1:1) to once-daily ozanimod hydrochloride (0. [...]
2018 - 10.1177/1352458518789884
Multiple sclerosis, Vol. 25 (july 2018) , p. 1255-1262  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
1 Arnold, D.
2 Arnold, D.L.
1 Arnold, Dirk
6 Arnold, Douglas Lorne
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem